Women's Health News

RSS

Advanced breast cancer patients can benefit from immunotherapy-chemotherapy combination

Patients with an aggressive form of advanced breast cancer can benefit from immunotherapy when used in combination with chemotherapy as first-line treatment, according to the results of a large international Phase III clinical trial published today in the New England Journal of Medicine and led by a researcher at the UPMC Hillman Cancer Center and the University of Pittsburgh School of Medicine.

23 Oct 2018

Study reveals new treatment option for women with advanced breast cancer resistant to hormone therapy

Treatment with the cyclin dependent kinase 4/6 inhibitor palbociclib achieves a clinically meaningful improvement in overall survival in patients with hormone receptor positive human epidermal growth factor receptor-2 negative advanced breast cancer that has relapsed or progressed on hormonal therapy, according to the final analysis of overall survival results from the PALOMA-3 study reported at ESMO 2018.

23 Oct 2018

Drugs approved for breast cancer treatment are effective and well tolerated in men

There is growing evidence that drugs approved for the treatment of breast cancer in women are also effective and well tolerated in men, according to the largest real-life study yet to investigate treatment and outcomes in men with breast cancer and two further studies to be reported at ESMO 2018.

23 Oct 2018

Organic food may protect against cancers finds study

The study published this week in the latest issue of the journal JAMA Internal Medicine reports that people who consume more organic foods are at a lower overall risk of developing cancer compared to people who do not. Some of the specific cancers avoided are non-Hodgkin lymphoma and postmenopausal breast cancer write the researchers.

23 Oct 2018

Plastics now commonly found in human stools

Nearly eight billion metric tons of plastic finds its way into the oceans each year. This huge amount of plastic either washes ashore or breaks down into tiny pieces that are less than 5 millimeters in diameter and are called microplastics.

22 Oct 2018

Study: Targeting specific genomic mutation in breast cancer improves survival

Targeting a common mutation in patients with hormone receptor positive (HR+) HER2 negative (HER2-) advanced breast cancer with the alpha-specific phosphatidylinositol-3-kinase (PI3K) inhibitor alpelisib significantly improves progression-free survival, according to late-breaking results reported at ESMO 2018.

22 Oct 2018

Study shows potential positive impact of group prenatal care on birth outcomes

A recent retrospective matched cohort study of more than 9,000 pregnant women found that women who received group prenatal care had a significantly lower risk of having a preterm birth or a low birth weight baby compared with women who received individual care only, after adjusting for number of individual care visits.

22 Oct 2018

Targeted drug and hormone therapy combination extends breast cancer survival

Combining a targeted drug with hormone therapy substantially extends survival for women with advanced breast cancer, a major clinical trial has found.

22 Oct 2018

Maintenance therapy with olaparib improves progression-free survival in advanced ovarian cancer patients

Two-year maintenance therapy with olaparib, a PARP (poly ADP ribose polymerase) inhibitor, olaparib, led to a substantial, unprecedented improvement in progression-free survival (PFS) in newly diagnosed patients with advanced ovarian cancer and a BRCA1 or 2 mutation, results from the phase 3 SOLO-1 trial show.

22 Oct 2018

Pfizer announces PALOMA-3 trial results in patients with HR+, HER2- metastatic breast cancer

Pfizer Inc. today announced detailed overall survival data from the PALOMA-3 trial, which evaluated IBRANCE (palbociclib) in combination with fulvestrant compared to placebo plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer whose disease progressed on or after prior endocrine therapy.

22 Oct 2018

LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer

AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., today announced detailed results from the Phase III SOLO-1 trial testing LYNPARZA (olaparib) 300 mg tablets twice-daily as a maintenance treatment for patients with newly diagnosed advanced BRCA-mutated ovarian cancer who were in complete or partial response following 1st-line standard platinum-based chemotherapy.

22 Oct 2018

Immunotherapy increases survival in some patients with metastatic triple negative breast cancer

Immunotherapy improves survival in some patients with metastatic triple negative breast cancer, according to late-breaking results from the IMpassion130 trial reported at the ESMO 2018 Congress in Munich.

22 Oct 2018

Phase III trial reports positive results with HDAC inhibitor in advanced breast cancer patients

Epigenetic therapy with histone deacetylase inhibitors is worth pursuing in hormone receptor positive advanced breast cancer, suggests a phase III trial reported today at the ESMO 2018 Congress in Munich.

22 Oct 2018

Zoledronic acid increases disease-free survival in premenopausal women with HR+ early breast cancer

Adjuvant treatment with the bone sparing drug zoledronic acid plus hormonal therapy with the aromatase inhibitor letrozole significantly increases disease-free survival compared to tamoxifen in premenopausal women with hormone receptor positive (HR+) early breast cancer, according to results reported at ESMO 2018 Congress in Munich.

22 Oct 2018

Immunotherapy trial offers new hope for people with aggressive breast cancer

There is new hope for people with an aggressive type of breast cancer, as an immunotherapy trial shows for the first time that lives can be extended in people with triple-negative breast cancer.

22 Oct 2018

ImmunoGen announces study results of platinum-resistant ovarian cancer therapy at ESMO 2018 Congress

ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced initial safety and preliminary anti-tumor activity from the FORWARD II expansion cohort assessing mirvetuximab soravtansine in combination with Merck's anti-PD-1 therapy, KEYTRUDA (pembrolizumab).

22 Oct 2018

Shorter course of trastuzumab could be an option for women with HER2+ early breast cancer

Women with HER2-positive early breast cancer with small tumours have similar disease-free survival and lower risk of cardiac toxicity with a nine-week course of adjuvant trastuzumab compared to those treated for one year, according to a subgroup analysis of the Short-HER trial reported at ESMO 2018 Congress in Munich.

22 Oct 2018

Women's Health News

Advanced breast cancer patients can benefit from immunotherapy-chemotherapy combination

Study reveals new treatment option for women with advanced breast cancer resistant to hormone therapy

Drugs approved for breast cancer treatment are effective and well tolerated in men

Organic food may protect against cancers finds study

Plastics now commonly found in human stools

Study: Targeting specific genomic mutation in breast cancer improves survival

Study shows potential positive impact of group prenatal care on birth outcomes

Targeted drug and hormone therapy combination extends breast cancer survival

Maintenance therapy with olaparib improves progression-free survival in advanced ovarian cancer patients

Pfizer announces PALOMA-3 trial results in patients with HR+, HER2- metastatic breast cancer

LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer

Immunotherapy increases survival in some patients with metastatic triple negative breast cancer

Phase III trial reports positive results with HDAC inhibitor in advanced breast cancer patients

Zoledronic acid increases disease-free survival in premenopausal women with HR+ early breast cancer

Immunotherapy trial offers new hope for people with aggressive breast cancer

ImmunoGen announces study results of platinum-resistant ovarian cancer therapy at ESMO 2018 Congress

Shorter course of trastuzumab could be an option for women with HER2+ early breast cancer

Not exercising is worse than smoking, diabetes or heart disease finds study

Breast cancer survival could be extended with two new drug combinations

Dysfunction of single gene leads to miscarriages

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Latest News